AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12505931 — intervention group
Group type: COMPARATOR
Intervention: Routine oxygen administration with 30% oxygen, balance nitrogen (Group A)
Number of subjects: 100
Study 10881121 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole
Number of subjects: 0
Study 9371353 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 100 mg oral capsule, administered five times a day for 3 days and a single dose on day 4
Number of subjects: 12
Study 9371353 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine 100 mg oral capsule with megestrol acetate 800 mg (40 mg/ml aqueous suspension) administered for 13 days
Number of subjects: 12
Study 8250430 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% alcohol (A)
Number of subjects: 311
Study 8250430 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercurochrome (M)
Number of subjects: 311
Study 8250430 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol and mercurochrome (AM)
Number of subjects: 311
Study 8250430 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine (C)
Number of subjects: 311
Study 3161531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (20-40 mg twice daily)
Number of subjects: 22
Study 3161531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31403367 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% topical minoxidil
Number of subjects: 90
Study 31403367 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% topical minoxidil
Number of subjects: 90
Study 31403367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 31438916 — intervention group
Group type: EXPERIMENTAL
Intervention: SNEA patients
Number of subjects: 32
Study 31438916 — intervention group
Group type: COMPARATOR
Intervention: AA patients
Number of subjects: 32
Study 31438916 — intervention group
Group type: COMPARATOR
Intervention: HS
Number of subjects: 32
Study 30012721 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational telephone call about LARC and SARC availability, effectiveness, and safety prior to surgical abortion.
Number of subjects: 234
Study 30012721 — intervention group
Group type: COMPARATOR
Intervention: Standardised notification about appointment logistics without contraception information.
Number of subjects: 234
Study 26683347 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively primed with a positively phrased Pain Catastrophizing Scale (PCS)
Number of subjects: 168
Study 26683347 — intervention group
Group type: COMPARATOR
Intervention: Negatively primed with the original Pain Catastrophizing Scale (PCS)
Number of subjects: 168
Study 26683347 — intervention group
Group type: COMPARATOR
Intervention: Not primed (control group)
Number of subjects: 168
Study 24568472 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Number of subjects: 173
Study 24568472 — intervention group
Group type: COMPARATOR
Intervention: Pirarubicin hydrochloride
Number of subjects: 173
Study 23939707 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap provision intervention
Number of subjects: 60
Study 23939707 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap and latrine cleaning materials
Number of subjects: 60
Study 23939707 — intervention group
Group type: COMPARATOR
Intervention: Control group (no soap provision)
Number of subjects: 60
Study 23939707 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention schools (soap provision)
Number of subjects: 60
Study 20012563 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulatory therapy with thalidomide or lenalidomide combined with dexamethasone
Number of subjects: 0
Study 20012563 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulatory therapy with thalidomide or lenalidomide combined with bortezomib
Number of subjects: 0
Study 20012563 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulatory therapy with thalidomide or lenalidomide combined with akt inhibitors
Number of subjects: 0
Study 20012563 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulatory therapy with thalidomide or lenalidomide combined with HDAC inhibitors
Number of subjects: 0
Study 20012563 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulatory therapy with thalidomide or lenalidomide combined with monoclonal antibodies
Number of subjects: 0
Study 18975051 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml of iopamidol 300 at an injection rate of 3.0 ml/s
Number of subjects: 30
Study 18975051 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml of iopamidol 300 at an injection rate of 3.7 ml/s
Number of subjects: 30
Study 18975051 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 ml of iopamidol 370 at an injection rate of 3.0 ml/s
Number of subjects: 30
Study 16637481 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial-coverage ceramic restorations (PCRs) made of IPS e.max Press, subjected to masticatory fatigue loading and thermal cycling.
Number of subjects: 96
Study 16637481 — intervention group
Group type: COMPARATOR
Intervention: Control group NP (unprepared molars)
Number of subjects: 96
Study 16637481 — intervention group
Group type: COMPARATOR
Intervention: Control group IN (MOD inlay preparation)
Number of subjects: 96
Study 19771709 — intervention group
Group type: EXPERIMENTAL
Intervention: Hate crime conditions (motivated by race, sexual orientation, or religion)
Number of subjects: 0
Study 19771709 — intervention group
Group type: COMPARATOR
Intervention: Non-hate crime condition
Number of subjects: 0
Study 19771709 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with prejudiced attitudes
Number of subjects: 0
Study 11304641 — intervention group
Group type: EXPERIMENTAL
Intervention: CODAS verapamil PM 200 mg dosed nightly
Number of subjects: 24
Study 11304641 — intervention group
Group type: COMPARATOR
Intervention: Immediate‐acting verapamil 80 mg dosed three times daily
Number of subjects: 24
Study 11304641 — intervention group
Group type: EXPERIMENTAL
Intervention: Both medications tested
Number of subjects: 24
Study 8630717 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg plus pseudoephedrine HCl 60 mg
Number of subjects: 676
Study 8630717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 676
Study 1450287 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing gum
Number of subjects: 0
Study 1450287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1450287 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (anticholinesterase inhibitor)
Number of subjects: 0
Study 2858839 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular interval (RI) group - buprenorphine 0.3 mg IV before anaesthesia, followed by sublingual buprenorphine 0.4 mg 6 hourly postoperatively
Number of subjects: 80
Study 2858839 — intervention group
Group type: COMPARATOR
Intervention: On demand (OD) group - meperidine 1 mg/kg on demand in recovery room, followed by ketobemidone 5 mg subcutaneously on demand
Number of subjects: 80
Study 2858839 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular interval (RI) group
Number of subjects: 80
Study 2858839 — intervention group
Group type: COMPARATOR
Intervention: On demand (OD) group
Number of subjects: 80
Study 31340846 — intervention group
Group type: EXPERIMENTAL
Intervention: Active abdominal functional electrical stimulation (FES) for 30 minutes, twice per day, 5 days per week until ICU discharge.
Number of subjects: 20
Study 31340846 — intervention group
Group type: COMPARATOR
Intervention: Sham (control) abdominal functional electrical stimulation for 30 minutes, twice per day, 5 days per week until ICU discharge.
Number of subjects: 20
Study 29278720 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad mood induction
Number of subjects: 91
Study 29278720 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy mood induction
Number of subjects: 91
Study 29278720 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral mood induction
Number of subjects: 91
Study 29278720 — intervention group
Group type: EXPERIMENTAL
Intervention: Age interaction with mood
Number of subjects: 91
Study 26169350 — intervention group
Group type: EXPERIMENTAL
Intervention: CBIT-VoIP
Number of subjects: 20
Study 26169350 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 20
Study 25436966 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive heat loading (PHL) at 39 °C
Number of subjects: 12
Study 25436966 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive heat loading (PHL) at 42 °C
Number of subjects: 12
Study 25436966 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive heat loading (PHL) at 43 °C
Number of subjects: 12
Study 25436966 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive heat loading (PHL) leg immersion at 42 °C
Number of subjects: 12
Study 25436966 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive heat loading (PHL) half immersion at 42 °C
Number of subjects: 12
Study 22146280 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load core stability exercises
Number of subjects: 109
Study 22146280 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load sling exercises
Number of subjects: 109
Study 22146280 — intervention group
Group type: COMPARATOR
Intervention: General exercises
Number of subjects: 109
Study 20225533 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with subcutaneous injections of Dp and Df extracts
Number of subjects: 40
Study 20225533 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immunotherapy)
Number of subjects: 40
Study 18627266 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg annual zoledronate (n = 17)
Number of subjects: 33
Study 18627266 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 33
Study 18320144 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-impregnated EVD catheters
Number of subjects: 39
Study 18320144 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard EVD catheters)
Number of subjects: 39
Study 15040821 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-magnitude, high-frequency mechanical stimuli (vibration) - 2.0 m/s2 peak to peak, 30 Hz, two 10-minute treatments/day
Number of subjects: 70
Study 15040821 — intervention group
Group type: COMPARATOR
Intervention: Placebo - standing on placebo devices for the same duration
Number of subjects: 70
Study 11562748 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation aromatase inhibitors
Number of subjects: 0
Study 11562748 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxanes
Number of subjects: 0
Study 11562748 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracyclines
Number of subjects: 0
Study 11562748 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Number of subjects: 0
Study 11562748 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0
Study 11562748 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 0
Study 11562748 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with stem cell support
Number of subjects: 0
Study 11562748 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HER2 monoclonal antibody Trastuzumab
Number of subjects: 0
Study 9265328 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised clinical trials
Number of subjects: 0
Study 7945601 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental loading intravenously
Number of subjects: 62
Study 2897172 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 1.5 micrograms/kg
Number of subjects: 80
Study 2897172 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 3.0 micrograms/kg
Number of subjects: 80
Study 2897172 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 4.5 micrograms/kg
Number of subjects: 80
Study 2897172 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 1.5 or 3.0 micrograms/kg
Number of subjects: 80
Study 2897172 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline, 0.03 ml/kg)
Number of subjects: 80
Study 30630380 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative fluid management protocol
Number of subjects: 30
Study 30630380 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 30408255 — intervention group
Group type: EXPERIMENTAL
Intervention: Basophil Activation Test (BAT) with cow's milk extract and major allergens (casein, α-lactalbumin, β-lactoglobulin)
Number of subjects: 86
Study 30408255 — intervention group
Group type: COMPARATOR
Intervention: Double-Blind Placebo-Controlled Food Challenge (DBPCFC)
Number of subjects: 86
Study 27634477 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated carbon nanoparticle lymphatic tracer
Number of subjects: 103
Study 27634477 — intervention group
Group type: COMPARATOR
Intervention: Routine radical thyroidectomy
Number of subjects: 103
Study 28361822 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (200-600 mg/day)
Number of subjects: 63
Study 28361822 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (4-8 mg/day)
Number of subjects: 63
Study 24021217 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (SSRI)
Number of subjects: 177
Study 24021217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 24021217 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (SSRI) with low-expressing serotonin transporter genotype
Number of subjects: 177
Study 24021217 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (SSRI) with high-expressing serotonin transporter genotype
Number of subjects: 177
Study 24021217 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (SSRI) with low-transcription 1A receptor genotype
Number of subjects: 177
Study 24021217 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (SSRI) with high-expressing genotypes in serotonin transporter, 1A, or 2A receptors
Number of subjects: 177
Study 22009189 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6-MP)
Number of subjects: 90
Study 19400893 — intervention group
Group type: EXPERIMENTAL
Intervention: Hookworm infection (10 hookworm larvae)
Number of subjects: 30
Study 19400893 — intervention group
Group type: COMPARATOR
Intervention: Histamine placebo
Number of subjects: 30
Study 17692137 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk with probiotics (Bifidobacterium longum BB536, Bifidobacterium spp. 420 and Lactobacillus acidophilus 145)
Number of subjects: 66
Study 17692137 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk with probiotics and inulin (4 g)
Number of subjects: 66
Study 17692137 — intervention group
Group type: COMPARATOR
Intervention: Control fermented milk
Number of subjects: 66
Study 15958324 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex Hongyibuxue oral solution
Number of subjects: 100
Study 15958324 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate
Number of subjects: 100
Study 12021222 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stenting in unstable angina
Number of subjects: 1205
Study 12021222 — intervention group
Group type: COMPARATOR
Intervention: Bypass surgery in unstable angina
Number of subjects: 1205
Study 12021222 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stenting in stable angina
Number of subjects: 1205
Study 12021222 — intervention group
Group type: COMPARATOR
Intervention: Bypass surgery in stable angina
Number of subjects: 1205
Study 9698951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 1 mg.kg-1 i.v. preoperative
Number of subjects: 60
Study 9698951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 1 mg.kg-1 i.v. postoperative
Number of subjects: 60
Study 9698951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7599807 — intervention group
Group type: EXPERIMENTAL
Intervention: -15 cm H2O Continuous Negative Pressure (CNP)
Number of subjects: 0
Study 7599807 — intervention group
Group type: EXPERIMENTAL
Intervention: -20 cm H2O Continuous Negative Pressure (CNP)
Number of subjects: 0
Study 7599807 — intervention group
Group type: EXPERIMENTAL
Intervention: +15 cm H2O Positive End-Expiratory Pressure (PEEP)
Number of subjects: 0
Study 7599807 — intervention group
Group type: COMPARATOR
Intervention: -10 cm H2O Continuous Negative Pressure (CNP)
Number of subjects: 0
Study 7599807 — intervention group
Group type: COMPARATOR
Intervention: +10 cm H2O Positive End-Expiratory Pressure (PEEP)
Number of subjects: 0
Study 2240674 — intervention group
Group type: EXPERIMENTAL
Intervention: 400-micrograms clonidine bolus followed by 10 micrograms/h clonidine infusion
Number of subjects: 60
Study 2240674 — intervention group
Group type: EXPERIMENTAL
Intervention: 800-micrograms clonidine bolus followed by 20 micrograms/h clonidine infusion
Number of subjects: 60
Study 2240674 — intervention group
Group type: COMPARATOR
Intervention: Saline bolus followed by 24-h saline infusion
Number of subjects: 60
Study 2240674 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms/h clonidine infusion
Number of subjects: 60
Study 2240674 — intervention group
Group type: EXPERIMENTAL
Intervention: 400-micrograms clonidine
Number of subjects: 60
Study 2240674 — intervention group
Group type: EXPERIMENTAL
Intervention: 800-micrograms clonidine
Number of subjects: 60
Study 2240674 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 60
Study 13230 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin hydrochloride
Number of subjects: 14
Study 13230 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 14
Study 30170012 — intervention group
Group type: EXPERIMENTAL
Intervention: Exparel (Liposomal Bupivacaine)
Number of subjects: 79
Study 30170012 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 79
Study 27697570 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline treatment
Number of subjects: 100
Study 27697570 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Control)
Number of subjects: 100
Study 25841300 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin-metformin
Number of subjects: 0
Study 25841300 — intervention group
Group type: COMPARATOR
Intervention: Acarbose-metformin
Number of subjects: 0
Study 24011551 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 24910
Study 24011551 — intervention group
Group type: COMPARATOR
Intervention: Control (clopidogrel or placebo)
Number of subjects: 24910
Study 21354682 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (1 tablet containing 1,000 mg of elemental lanthanum)
Number of subjects: 31
Study 21354682 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate (three 800-mg tablets)
Number of subjects: 31
Study 21354682 — intervention group
Group type: COMPARATOR
Intervention: Standard meal alone
Number of subjects: 31
Study 21354682 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 31
Study 21354682 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Number of subjects: 31
Study 19390210 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C
Number of subjects: 50
Study 19390210 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum creatinine
Number of subjects: 50
Study 19390210 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine-based formulae
Number of subjects: 50
Study 17069768 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (13.3 +/- 3 mg/day)
Number of subjects: 40
Study 17069768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15279523 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral group therapy
Number of subjects: 90
Study 15279523 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure group therapy without explicit cognitive interventions
Number of subjects: 90
Study 15279523 — intervention group
Group type: COMPARATOR
Intervention: Wait‐list control condition
Number of subjects: 90
Study 11493040 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored letter providing feedback on consumption of target foods, stage‐matched nutrition education booklets, diet‐health endorsement from PCPs, and two motivational counseling telephone calls.
Number of subjects: 230
Study 11493040 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified in detail).
Number of subjects: 230
Study 9506731 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg prednisolone daily for 3.7 +/- 0.6 months (range, 1-6)
Number of subjects: 9
Study 7511357 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40
Study 7511357 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 40
Study 2893592 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201-995 (50 micrograms subcutaneously prior to meal ingestion)
Number of subjects: 12
Study 2893592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30580089 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Pelvic Floor Muscle Training (PFMT) and biofeedback plus conservative treatment
Number of subjects: 98
Study 30580089 — intervention group
Group type: COMPARATOR
Intervention: Attention-control massage treatment plus conservative treatment
Number of subjects: 98
Study 28735217 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg zopiclone
Number of subjects: 16
Study 28735217 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg zopiclone
Number of subjects: 16
Study 28735217 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses (5mg and 10mg zopiclone)
Number of subjects: 16
Study 25987795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-reduced diet (FRD)
Number of subjects: 182
Study 25987795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-reduced diet (FRD) with provocation test
Number of subjects: 182
Study 25987795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose breath tests (FBT)
Number of subjects: 182
Study 25987795 — intervention group
Group type: COMPARATOR
Intervention: Control group (no FRD)
Number of subjects: 182
Study 24352393 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone graft
Number of subjects: 48
Study 24352393 — intervention group
Group type: COMPARATOR
Intervention: No allogeneic bone graft (Control)
Number of subjects: 48
Study 21804212 — intervention group
Group type: COMPARATOR
Intervention: Silodosin 2 mg
Number of subjects: 82
Study 21804212 — intervention group
Group type: COMPARATOR
Intervention: Silodosin 4 mg
Number of subjects: 82